Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Vectibix (Panitumumab), folic acid, 5-FU, oxaliplatin, irinotecan
FOLFOXIRI+ Panitumumab · 1 trial · 1 indication
RECIST
| Arm | Type | Description |
|---|---|---|
| A (FOLFOXIRI + Panitumumab) | EXPERIMENTAL | FOLFOXIRI + Panitumumab |
| B (FOLFOXIRI) | ACTIVE_COMPARATOR | FOLFOXIRI |
| Name | Type | Description |
|---|---|---|
| FOLFOXIRI + Panitumumab | DRUG | irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles |
| FOLFOXIRI | DRUG | irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles |
Inclusion Criteria: * Cohort I: Histologically confirmed and definitively inoperable or irresectable metastatic colorectal cancer. Focus on patients with large tumor load at metastatic sites and/or symptomatic metastatic disease * Cohort II: Chance of secondary resection with curative intent define...
Top 20 of 80 competitors
FOLFOXIRI+ Panitumumab is studied for metastatic colorectal cancer. It combines the FOLFOXIRI chemotherapy regimen with panitumumab, an EGFR-targeted antibody. The combination has been evaluated in a biomarker-selected patient population in a Phase 2 trial.
Amgen Inc. (ticker: AMGN) develops panitumumab, the targeted agent in the FOLFOXIRI+ Panitumumab combination. Amgen is the company associated with this drug asset.
FOLFOXIRI+ Panitumumab is in Phase 2 development. The single registered trial, NCT01328171, has completed. The drug is investigational and is not approved for use.
FOLFOXIRI+ Panitumumab has been studied in one clinical trial: NCT01328171, titled FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI). This completed Phase 2 trial enrolled 93 patients in Germany and was active-controlled and randomized.